Sequoia Financial Advisors LLC Has $1.64 Million Stock Holdings in Teleflex Incorporated (NYSE:TFX)

Sequoia Financial Advisors LLC lifted its holdings in Teleflex Incorporated (NYSE:TFX) by 2.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 6,637 shares of the medical technology company’s stock after purchasing an additional 153 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Teleflex were worth $1,641,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TFX. Vanguard Group Inc. lifted its position in Teleflex by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 5,550,727 shares of the medical technology company’s stock valued at $1,255,408,000 after purchasing an additional 96,711 shares during the period. Janus Henderson Group PLC boosted its stake in Teleflex by 12.0% in the first quarter. Janus Henderson Group PLC now owns 5,409,317 shares of the medical technology company’s stock valued at $1,223,424,000 after acquiring an additional 581,312 shares during the last quarter. Cooke & Bieler LP grew its holdings in Teleflex by 23.3% during the 2nd quarter. Cooke & Bieler LP now owns 912,797 shares of the medical technology company’s stock worth $191,989,000 after acquiring an additional 172,335 shares during the period. TD Asset Management Inc raised its position in shares of Teleflex by 12.0% during the 2nd quarter. TD Asset Management Inc now owns 456,081 shares of the medical technology company’s stock valued at $95,928,000 after acquiring an additional 48,832 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Teleflex by 6.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 425,647 shares of the medical technology company’s stock valued at $89,526,000 after acquiring an additional 26,325 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Trading Down 0.9 %

NYSE TFX opened at $235.62 on Friday. Teleflex Incorporated has a one year low of $177.63 and a one year high of $257.85. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.58 and a quick ratio of 1.44. The firm has a market cap of $11.10 billion, a P/E ratio of 42.30, a P/E/G ratio of 2.15 and a beta of 1.16. The stock’s 50-day moving average is $241.19 and its 200-day moving average is $223.48.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.33 by $0.09. Teleflex had a return on equity of 14.51% and a net margin of 8.76%. The business had revenue of $749.70 million during the quarter, compared to analysts’ expectations of $762.98 million. During the same period in the prior year, the business earned $3.41 EPS. Teleflex’s revenue for the quarter was up .9% compared to the same quarter last year. Sell-side analysts anticipate that Teleflex Incorporated will post 13.97 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Thursday, August 15th were given a $0.34 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $1.36 annualized dividend and a yield of 0.58%. Teleflex’s dividend payout ratio is currently 24.42%.

Analysts Set New Price Targets

Several research firms have recently issued reports on TFX. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $205.00 to $245.00 in a research report on Monday, July 1st. Royal Bank of Canada raised their target price on Teleflex from $260.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Stephens upped their price target on Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Truist Financial lifted their price objective on shares of Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a research note on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $268.86.

Insider Activity at Teleflex

In other Teleflex news, Director Stuart A. Randle sold 2,674 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the transaction, the director now owns 5,496 shares in the company, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.43% of the stock is currently owned by insiders.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.